| Name | Title | Contact Details |
|---|
SimBioSys Inc is a Etobicoke, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
BIND Therapueitics is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BD Biosciences - Canada is a Mississauga, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Med-Metrix is a leading provider of performance management analytics, consulting, extended business office, and revenue recovery services to the healthcare industry. Our firm was founded by a veteran management team with a successful track record providing superior service and technology to Hospitals.
Impact Biomedicines, Inc. (Impact) is pioneering the development of life-changing treatments for patients with myeloproliferative neoplasms and other cancers. Led by a highly skilled and devoted team, Impact is advancing a late-stage pipeline centered around fedratinib, a potent and highly selective oral small molecule JAK2 kinase inhibitor, which is being developed initially for the treatment of myelofibrosis (MF) and polycythemia vera (PV). Impact was formed in 2016 after acquisition of Sanofi’s full rights for the global development and commercialization of fedratinib. The Impact team intends to pursue multiple clinical indications for fedratinib to maximize its potential as a best-in-class therapy for JAK2-dependent diseases.